Pharmacokinetic Study of CVT-301 (Levodopa Inhalation Powder)
- Registration Number
- NCT03887884
- Lead Sponsor
- Acorda Therapeutics
- Brief Summary
This study will be an open-label, randomized, multi-center, 2-way crossover Pharmacokinetic PK evaluation of a single inhaled dose of CVT-301 84 mg and a single oral dose of carbidopa/levodopa CD/LD 25 mg/100 mg (Sinemet®) under fed conditions in Parkinson's Disease (PD) patients who regularly take CD/LD.
- Detailed Description
The study duration includes a screening period followed by an overnight stay in the center (4 days, 3 nights) to complete 2 treatments, including a 48-hour interval between the treatments, and a follow-up phone call 1-2 days after discharge from the center.
On each of two treatment days, subjects will consume a standard high fat meal and then receive either (A) a single inhaled dose of CVT-301 or (B) a single dose of oral CD/LD followed by Pharmacokinetic (PK) sampling for 4 hours. A crossover design will be used such that each subject receives both Treatment A and Treatment B over the 2 treatment days, randomized 1:1 to the treatment sequence AB or BA.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 23
- Men and women between the ages of 30 and 85 years, inclusive.
- Have idiopathic PD (i.e., not induced by drugs or other diseases) as defined by fulfilling Steps 1 and 2 of the United Kingdom (UK) Brain Bank criteria, diagnosed after the age of 30 years.
- Classified as Stage 1 to 3 (in the ON state) on the modified Hoehn and Yahr scale for staging of PD severity.
- Stable on other non levodopa PD medications for at least 4 weeks prior to the Screening Visit.
- Subjects must have normal cognition as confirmed by a score of ≥ 25 on the Mini Mental State Examination (MMSE), performed in the ON state.
- Forced expiratory volume in one second (FEV1) ≥60% of predicted for race, age, sex, and height and FEV1/FVC (forced vital capacity) ratio ≥70%.
- Body Mass Index (BMI) between 18 - 32 kg/m2, inclusive.
- Any flu-like syndrome or other respiratory infections within 2 weeks prior to the Screening Visit.
- Chronic obstructive pulmonary disease (COPD), asthma, or other chronic respiratory disease within the last 5 years.
- History of any cancer in the past 5 years with the exception of successfully treated basal cell carcinoma.
- Narrow angle glaucoma or a history of peptic ulcer disease less than 1 year prior to screening.
- Previous surgery for PD (including but not limited to deep brain stimulation or cell transplantation).
- Current use of nicotine patch or tobacco-containing products including cigarettes, electronic cigarettes, cigars, chewing tobacco, pipe tobacco or snuff or use within 4 weeks prior to the Screening Visit, or expected use during the study.
- Marijuana smoking within 4 weeks prior to the Screening Visit, or expected smoking/inhalation during the study.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Sinemet Sinemet Single oral dose of Carbidopa/Levodopa 25 mg/100 mg CVT-301 CVT-301 Single inhaled dose of CVT-301 84 mg
- Primary Outcome Measures
Name Time Method Maximum plasma concentration of a single inhaled dose of CVT-301 84 mg and an oral dose of CD/LD 25 mg/100 mg (carbidopa/levodopa) in patients with Parkinson's disease. 4 days, 3 nights Maximum observed plasma drug concentration (Cmax) of a single inhaled dose of CVT-301 84 mg and an oral dose of CD/LD 25 mg/100 mg in patients with Parkinson's disease (PD) in a fed state.
Total plasma concentration of a single inhaled dose of CVT-301 84 mg and an oral dose of CD/LD 25 mg/100 mg (carbidopa/levodopa) in patients with Parkinson's disease. 4 days, 3 nights Area under the plasma concentration curve from time 0 to the concentration at 4 hours (AUCo-4h) of a single inhaled dose of CVT-301 84 mg and an oral dose of CD/LD 25 mg/100 mg in patients with Parkinson's disease (PD) in a fed state.
Terminal half-life of a single inhaled dose of CVT-30184 mg and an oral dose of CD/LD 25 mg/100 mg (carbidopa/levodopa) in patients with Parkinson's disease. 4 days, 3 nights Terminal half-life (t1/2)of a single inhaled dose of CVT-30184 and an oral dose of CD/LD 25 mg/100 mg in patients with Parkinson's disease (PD) in a fed state.
Time to maximum observed plasma drug concentration of a single inhaled dose of CVT-301 84 mg and an oral dose of CD/LD 25 mg/100 mg (carbidopa/levodopa) in patients with Parkinson's disease. 4 days, 3 nights Time to maximum observed plasma drug concentration (Tmax) of a single inhaled dose of CVT-301 84 mg and an oral dose of CD/LD 25 mg/100 mg in patients with Parkinson's disease (PD) in a fed state.
- Secondary Outcome Measures
Name Time Method Columbia-Suicide Severity Rating Scale (C-SSRS). 4 days, 3 nights To evaluate the safety and tolerability of a single inhaled dose of CVT-301 84 mg and an oral dose of CD/LD 25/100 mg) under fed conditions in PD patients using the Columbia-Suicide Severity Rating Scale (C-SSRS). The (C-SSRS) is an assessment tool that evaluates suicidal ideation and behavior. Scale range: Yes or No response to 10 questions, with minimum to maximum range of 0 to 10. Lower score represents better outcomes. Subscales not applicable.
Incidence of adverse events. 4 days, 3 nights To evaluate the safety and tolerability of a single inhaled dose of CVT-301 84 mg and an oral dose of CD/LD 25/100 mg) under fed conditions in PD patients by accessing adverse events.
Trial Locations
- Locations (5)
Acorda Site #1005
🇺🇸Hallandale Beach, Florida, United States
Acorda Site #1004
🇺🇸Atlanta, Georgia, United States
Acorda Site #1002
🇺🇸Orlando, Florida, United States
Acorda Site #1003
🇺🇸Long Beach, California, United States
Acorda Site #1001
🇺🇸Farmington Hills, Michigan, United States